- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03225924
Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy
Phase Ib - II Study of Entospletinib (ENTO) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients With aaIPI>=1 Treated by Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone (R-CHOP)
The primary objective of the phase Ib of the study is to determine the recommended phase 2 dose (RP2D) for entospletinib (ENTO) in patients treated with R-CHOP.
The primary objective of the phase II is to determine the complete metabolic response (CMR) rate by the Lugano classification 2014 (Deauville scale 1-3) at the end of treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bruxelles, Belgium, 1000
- Institut Jules Bordet
-
Bruxelles, Belgium, 1200
- Clinique Universite Catholique de Louvain Saint-Luc
-
Gent, Belgium, 9000
- University Hospital Gent
-
Haine-Saint-Paul, Belgium, 7100
- Hopital Joliment
-
Kortrijk, Belgium, 8500
- Az Groeninge
-
Yvoir, Belgium
- UCL Namur
-
-
-
-
-
Bourg-en-Bresse, France, 0100
- CH de Bourg en Bresse
-
Caen, France
- CHU côte de Nacre
-
Créteil, France
- CHU Henri Mondor
-
Dijon, France
- CHU de Dijon
-
Le Chesnay, France, 78150
- CH de Versailles - Hôpital André Mignot
-
Le Mans, France, 72000
- Clinique Victor Hugo
-
Limoges, France, 87042
- CHU de Limoges - Hôpital Dupuytren
-
Lyon, France
- CHU Lyon Sud
-
Lyon, France, 69337
- Clinique de la Sauvegarde
-
Montpellier, France
- CHU Montpellier
-
Mulhouse, France, 68070
- Ch Region Mulhouse Et Sud Alsace
-
Paris, France, 75015
- Hopital Necker Paris
-
Pessac, France, 33604
- CHU de Bordeaux
-
Pringy, France, 74374
- Ch Annecy Genevois
-
Reims, France, 51092
- CHU de Reims - Hôpital Robert Debré
-
Rennes, France, 35033
- CHU de Rennes - Pontchaillou
-
Roubaix, France, 59056
- Ch de Roubaix-Hopital Victor Provo
-
Toulouse, France, 31059
- IUCT Oncopole de Toulouse
-
Tours, France, 37044
- Hôpital Bretonneau- Centre H. Kaplan
-
Valenciennes, France, 59322
- CH de Valenciennes
-
Vandœuvre-lès-Nancy, France, 54511
- CHRU de Nancy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with histologically confirmed de novo DLBCL (CD20 positive) (cf section 20.6 - Appendix 4)
- Age between 60 and 80 years included, on the day of the informed consent document signature
- Age adjusted International Prognosis Index (aaIPI) score ≥ 1
- No prior treatment for DLBCL. However prephase treatment with 1mg/kg/day prednisone or equivalent, for a maximum of 14 days, is permitted prior to begin the treatment
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (0 or 1 only for phase 1b)
- Life expectancy of ≥ 90 days (3 months) before starting Entospletinib
- Signed informed consent
- At least one bi-dimensionally measurable lesion defined as at least one node or tumor lesion on CT scan ≥ 1.5 cm
- fluorodeoxyglucose (FDG) positron emission tomography (PET-CT) performed at baseline with a FDG positive result
Adequate hematologic functions defined as follows (unless secondary to bone marrow involvement by lymphoma):
- Absolute neutrophil count (ANC) > 1.5 X 10^9 G/l and
- Platelets count ≥ 75 X 10^9/l without platelet transfusion dependency during the last 7 days and
- Haemoglobin level > 9 g/dl (may receive transfusion)
Adequate liver function defined as follows:
- Total bilirubin <1.5 upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome and
- Alkaline phosphatase (in absence of bone disease), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 X ULN
- Adequate renal function as calculated by a creatinine clearance > 40 ml/min by local institutional formula
- Patients with prior Hepatitis B must be given antiviral prophylaxis and hepatitis B virus (HBV) DNA monitored; Patients with prior Hepatitis C are eligible if, hepatitis C virus (HCV) RNA is undetectable.
- Left ventricular ejection fraction (LVEF) ≥ 50% of echocardiography or multiple gated acquisition (MUGA) scan
- Adequate tissue for central retrospective testing for cell of origin (10-15 slides of tumor biopsy must be available at baseline)
Heterosexually active females of childbearing potential (as defined in the protocol) must:
- have a negative serum pregnancy test at baseline and prior to the first study drug administration (C1D-4)
- have practiced at least 1 reliable method of contraception for at least 2 months prior to the first study drug administration (C1D-4)
- agree to utilize highly effective methods of contraception (as defined in the protocol) from Cycle 1 Day -4 until 12 months following the last treatment administration
- Heterosexually active males with partners of childbearing potential must agree to use reliable forms of contraception during treatment and up to 12 months after last treatment administration
- Male subjects must agree to avoid sperm donation from Cycle 1 Day -4 until 12 months following the last treatment administration
Exclusion Criteria:
- Central nervous system or meningeal involvement with DLBCL
- Contraindication to any drug contained in the chemotherapy regimen
- Prior treatment with Entospletinib or other spleen tyrosine kinase (SYK ) inhibitor
Patients with a prior history of other malignancy, exceptions include:
- a subject who has been disease-free after curative local treatment (surgical resection) for at least 3 years,
- a subject with a history of a completely resected non-melanoma skin cancer or in situ carcinoma with surgical complete excision.
- Patients taking current therapy with proton pump inhibitors and current therapy with medicines that are strong Cytochrome P450 3A (CYP3A) or CYP2C9 inducers, or moderate CYP2C9 inducers.
- Ongoing active pneumonitis
- Peripheral sensory or motor neuropathy grade > 1.
- Major surgery within 4 weeks before first dose of study drug (minor procedures including transcutaneous biopsy, central line placement are permitted at any time)
- Inability to take oral medication or malabsorption syndrome or any other uncontrolled gastrointestinal condition that would impair ability to take entospletinib
- Significant cardiovascular impairment: congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of first dose of entospletinib or ventricular arrhythmia
- Active infection as judged by the investigator
- Known hypersensitivity to ENTO
- Congenital immunodeficiency or known HIV (human immunodeficiency virus infection) or active viral hepatitis B or C
- Any other major illness that in the investigator's judgement, will substantially increase the risk associated with the subject's participation in the study
- Subjects who have undergone a solid organ transplant and stem cell transplant
- Previous treatment for B cell lymphoma or Richter's transformation
- Primary Mediastinal B Cell Lymphoma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Entospletinib + Rituximab + Cyclophosphamide + Doxorubicine + Vincristine + Prednisone
|
200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
Other Names:
cycles of 21 days - 375mg/m²
Other Names:
cycles of 21 days - 750 mg/m²
cycles of 21 days - 50mg/m²
cycles of 21 days - 1.4mg/m²
cycles of 21 days - 40mg/m²
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: recommended phase 2 dose
Time Frame: 6 months
|
To determine the recommended phase 2 dose for Entospletinib
|
6 months
|
Phase II: Complete Metabolic Response (CMR) rate at the end of treatment
Time Frame: 168 days
|
To determine the CMR rate by the Lugano classification 2014 (Deauville scale 1-3) at the end of treatment
|
168 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gilles Salles, Hospices Civils de Lyon
- Principal Investigator: Emmanuelle Tchernonog, University Hospital, Montpellier
- Principal Investigator: Julien Depaus, UCL Namur
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Antibiotics, Antineoplastic
- Cyclophosphamide
- Rituximab
- Prednisone
- Doxorubicin
- Vincristine
Other Study ID Numbers
- ENTO-R-CHOP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on DLBCL
-
Fondazione Italiana Linfomi - ETSJanssen-Cilag S.p.A.Recruiting
-
The First Affiliated Hospital with Nanjing Medical...RecruitingEBV-Positive DLBCL, NosChina
-
The First Affiliated Hospital with Nanjing Medical...RecruitingDLBCL | Untreated | MYC Gene RearrangementChina
-
Memorial Sloan Kettering Cancer CenterActinium PharmaceuticalsRecruitingDiffuse Large B-cell Lymphoma | B-ALL | DLBCL | DLBCL, Nos Genetic Subtypes | B ALL | Dlbcl-Ci | DLBCL Unclassifiable | DLBCL Activated B-Cell Type | DLBCL Germinal Center B-Cell Type | HGBL | HGBL, NosUnited States
-
Acerta Pharma BVTerminatedDLBCL | Richter SyndromeUnited Kingdom, United States
-
The Lymphoma Academic Research OrganisationCHU de NancyCompleted
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
University Hospital, SaarlandCompletedDLBCL | Old Age; DebilityGermany
-
Beijing InnoCare Pharma Tech Co., Ltd.Recruiting
-
The Affiliated Hospital of Qingdao UniversityNot yet recruiting
Clinical Trials on Entospletinib
-
Gilead SciencesTerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Non-FL Indolent Non-Hodgkin's LymphomaUnited States, Canada
-
Gilead SciencesCompletedOncologyUnited States, New Zealand, Germany
-
Gilead SciencesGerman CLL Study GroupCompleted
-
Gilead SciencesTerminatedNon-Hodgkin LymphomaUnited States, France
-
Gilead SciencesTerminatedMantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin's LymphomaUnited States
-
University of South FloridaBaxter Healthcare CorporationUnknownSpinocerebellar AtaxiasUnited States
-
Gilead SciencesActive, not recruitingB-cell MalignanciesUnited States, United Kingdom, France
-
Kronos BioTerminatedNucleophosmin 1-mutated Acute Myeloid LeukemiaIsrael, Spain, France, United States, Czechia, Hungary, Korea, Republic of, Germany, Italy, Poland, Brazil, Canada
-
Alexey Danilov, MDGilead Sciences; Oregon Health and Science UniversityCompletedAnemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Hairy Cell Leukemia | Richter Syndrome | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Grade 1 Follicular... and other conditionsUnited States
-
Gilead SciencesTerminatedAcute Myeloid LeukemiaUnited States, Canada, Germany